Bcl-2 family members as molecular targets in cancer therapy
Bcl-2 family members as molecular targets in cancer therapy
复制标题
DOI：
10.1016/j.bcp.2008.06.009
复制
发表时间：
2008-10-15
影响因子：
5.8
通讯作者：
Naval, Javier
中科院分区：
文献类型：
--
作者：
Marzo, Isabel;Naval, Javier
逃避凋亡通常是癌细胞的标志，并且与化疗抗性或肿瘤复发相关。来自Bcl-2家族的蛋白质是细胞凋亡内在途径的关键调节剂，控制不归点并设定阈值以响应化学损伤而启动死亡机制。因此，Bcl-2蛋白已成为开发新型抗癌药物的有吸引力的靶标。目前的药理学方法集中在使用肽、小抑制分子或反义寡核苷酸来中和抗凋亡Bcl-2蛋白，降低阈值并促进癌细胞的凋亡。我们在这里讨论Bcl-2靶向抗癌疗法的发展的最新进展。(C)2008年爱思唯尔公司All rights reserved.
Escape from apoptosis is often a hallmark of cancer cells, and is associated to chemotherapy resistance or tumor relapse. Proteins from the Bcl-2 family are the key regulators of the intrinsic pathway of apoptosis, controlling the point-of no-return and setting the threshold to engage the death machinery in response to a chemical damage. Therefore, Bcl-2 proteins have emerged as an attractive target to develop novel anticancer drugs. Current pharmacological approaches are focused on the use of peptides, small inhibitory molecules or antisense oligonucleotides to neutralize antiapoptotic Bcl-2 proteins, lowering the threshold and facilitating apoptosis of cancer cells. We discuss here recent advances in the development of Bcl-2 targeted anticancer therapies. (C) 2008 Elsevier Inc. All rights reserved.